Loading
The laboratory validation of Personalis' whole-genome blood test for leftover cancer, which detected tumour DNA at a few parts per million.
NeXT Personal uses whole-genome sequencing of tumour and matched normal to identify up to about 1,800 patient-specific somatic variants for a personalised panel, sequenced in plasma cell-free DNA. Validation used panels from two cell lines and 123 patients across nine cancer types. The detection threshold was 1.67 parts per million and the 95 per cent limit of detection 3.45 parts per million; the assay was linear from 0.8 to 300,000 parts per million (Pearson 0.9998), precision ranged from a coefficient of variation of 12.8 to 3.6 per cent across 25 to 25,000 parts per million, and specificity measured 100 per cent against a 99.9 per cent target.
Personalised whole-genome designs can detect tumour DNA at a few parts per million. The panel favours variants present at high fraction in the tumour, so it is built to detect the trunk, not to tell branches apart.
Shares Naming which clone or phenotype is left after treatment, ctDNA MRD positivity (molecular residual disease after curative treatment), Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD).
Shares NeXT Personal Dx, ctDNA MRD positivity (molecular residual disease after curative treatment), Tumour-informed versus tumour-naive ctDNA assays, Whole-exome & whole-genome sequencing.
Shares NeXT Personal Dx, ctDNA MRD positivity (molecular residual disease after curative treatment), Tumour-informed versus tumour-naive ctDNA assays, Whole-exome & whole-genome sequencing.
Shares Oncotarget, Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares NeXT Personal Dx, ctDNA MRD positivity (molecular residual disease after curative treatment), Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD).
Shares Naming which clone or phenotype is left after treatment, ctDNA MRD positivity (molecular residual disease after curative treatment), Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD).
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Naming which clone or phenotype is left after treatment, Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/